| Full text | |
| Author(s): |
Lainetti, Patricia de Faria
[1]
;
Zuliani, Fernanda
[1]
;
Leis-Filho, Antonio Fernando
[1]
;
Fonseca Alves, Ricardo Henrique
[2]
;
Fonseca-Alves, Carlos Eduardo
[1, 3]
Total Authors: 5
|
| Affiliation: | [1] Sao Paulo State Univ UNESP, Sch Vet Med & Anim Sci, Dept Vet Surg & Anim Reprod, BR-18618681 Botucatu, SP - Brazil
[2] Harvard Univ, John A Paulson Sch Engn & Appl Sci, Cambridge, MA 02138 - USA
[3] Univ Paulista UNIP, Inst Hlth Sci, BR-17048290 Bauru, SP - Brazil
Total Affiliations: 3
|
| Document type: | Review article |
| Source: | PROCESSES; v. 8, n. 5 MAY 2020. |
| Web of Science Citations: | 0 |
| Abstract | |
Controlled drug delivery systems can be used to carry several anticancer agents, including classical chemotherapeutic agents such as doxorubicin, paclitaxel or cisplatin, and are also used for the encapsulation of tyrosine kinase inhibitors and monoclonal antibodies. Usually, the controlled systems are used to decrease drug toxicity, increase local drug concentration or target specific organs or systems. In dogs, liposomal doxorubicin is the most known controlled drug delivery vehicle in veterinary medicine. However, several antitumor drugs can be encapsulated within these systems. Since the delivery vehicles are a relatively new topic in veterinary oncology, this review aims to discuss the current knowledge regarding the controlled drug delivery vehicles and discuss the current challenges and future direction of its use in veterinary oncology. (AU) | |
| FAPESP's process: | 15/25400-7 - In vitro and molecular characterization of canine prostatic cells and evaluation of antitumor response against target drugs |
| Grantee: | Carlos Eduardo Fonseca Alves |
| Support Opportunities: | Scholarships in Brazil - Post-Doctoral |